Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Biotechs, Big Pharma In Cancer Drug Pacts
by Michael McCoy
July 4, 2011
| A version of this story appeared in
Volume 89, Issue 27
Forma Therapeutics has granted Roche’s Genentech unit exclusive rights to acquire a preclinical small-molecule program that targets an undisclosed cancer. Forma says the agreement involves “many exciting molecules” that it identified in less than 18 months. Meanwhile, PTC Therapeutics and AstraZeneca have formed a small-molecule oncology drug discovery program based on PTC’s Gene Expression Modulation by Small Molecules technology. Both biotech firms are entitled to up-front payments, research funding, and milestone payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter